Other
Arteriovenous Fistula
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Arteriovenous Fistula is an early-stage landscape with 0 programs across 2 companies. The most active players are Takeda, Cyathus Exquirere Pharmaforschungsgmbh.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
13
clinical trials
Completed7 · 54%
Unknown status2 · 15%
Terminated2 · 15%
Active, not recruiting1 · 8%
Withdrawn1 · 8%
Clinical Trials
Trial Activity
13 trials
Effects of Heparin on Arteriovenous Fistula Patency
Completed·—·Phase 4·NCT02493504·150 enrolled
Comparison of Infraclavicular Brachial Plexus Block and Local Anesthesia in Arteriovenous Fistula Surgeries and Their Effects on Tissue Oxygen Saturation
Completed·—·N/A·NCT06416111·60 enrolled
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Terminated·—·N/A·NCT02164318·11 enrolled
High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study
Withdrawn·—·Phase 1/2·NCT03188978
Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery
Unknown status·—·Phase 4·NCT02447796·48 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)